Socrodeucitinib
Socrodeucitinib (Compound Example 58) is an orally active and selective tyrosine kinase 2 (TYK2) inhibitor with an IC50 value of 1.41 nM. Socrodeucitinib exerts anti-inflammatory activity by inhibiting TYK2-mediated cytokine signaling pathways and reducing the secretion of inflammatory factors. Socrodeucitinib is promising for research of autoimmune diseases such as psoriasis and inflammatory diseases[1].
Product Specifications
CAS Number
2457365-35-2
UNSPSC
12352005
Target
JAK
Related Pathways
Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Smiles
COC1=C(C2=NN(C3CC3)C=N2)C=CC=C1NC4=C(N=NC(NC(C5CC5)=O)=C4)C(NC([2H])([2H])[2H])=O
Molecular Formula
C22H21D3N8O3
Molecular Weight
451.50
References & Citations
[1]Gao P, et al. Pyridazine derivative inhibitor, and preparation method and application thereof. WO2020156311A1. 2020-08-06.
Shipping Conditions
Room temperature
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported
Isoform
Tyk2
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Recombinant Human Peptidyl-prolyl cis-trans isomerase FKBP11 (FKBP11)
Recombinant Human Peptidyl-prolyl cis-trans isomerase FKBP11 (FKBP11)
Recombinant Human Peptidyl-prolyl cis-trans isomerase FKBP11 (FKBP11)
